Syndax Pharmaceuticals (SNDX) PT Lowered to $37 at UBS

May 13, 2026 8:42 AM

UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $37.00 (from $38.00) while maintaining a Buy rating.

No results found